Oliver Schacht, CEO of OpGen looks at why technologies including artificial intelligence and machine learning could be key to combatting antimicrobial resistance.
Oliver Schacht, CEO of precision medicine and genomics analysis company OpGen explores what we need to do to improve our fight against antimicrobial resistance (AMR).
